Inhibitor Therapeutics Inc

Inhibitor Therapeutics operates with a negative equity position of -$1,291,910 and a cash and equivalents balance of $2,375,490, indicating a liquidity cushion despite a negative net income of -$3,300,340 and operating loss of -$3,426,650. The company's current ratio of 3.19 suggests strong short-term liquidity, with total assets of $2,511,310 and total liabilities of $3,803,220. However, the absence of long-term debt and a debt-to-equity ratio of 0.0 indicate no leverage in the capital structure. Profitability metrics show a return on equity of 2.55, which is positive but modest, while the return on assets is negative at -1.31, reflecting the company's operational losses and asset underperformance. These figures are not directly comparable to industry medians due to the absence of a defined cohort for this company's specific focus on repurposed drugs for proliferation disorders. The company's revenue is reported as $0, and there is no disclosed segment or geographic breakdown in the provided data, making it impossible to assess revenue concentration or geographic exposure. The company's operations are entirely focused on the development of therapies for BCC, prostate, and lung cancers in the United States using itraconazole. The company's growth trajectory is not quantifiable due to the absence of historical revenue data and forward-looking guidance. The company is in the development phase and has not yet generated revenue, with a negative operating cash flow of -$3,231,370. The company's future growth will depend on the success of its clinical trials and the commercialization of its therapies. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is low, and no adjustments have been applied to the valuation metrics. The company's risk profile is primarily operational, with the risk of clinical trial failure and regulatory hurdles being the main concerns. There are no recent events or filings disclosed in the provided data that would impact the company's operations or financial position. The company's intellectual property includes issued U.S. patents related to the treatment of cancer patients using itraconazole. The company's future success will depend on the successful development and commercialization of its therapies.